Library Open Repository
ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.
Ding, C and Xu, J and Li, J (2008) ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Current Opinion in Investigational Drugs, 9 (5). pp. 515-522. ISSN 1472-4472
ABT-874.pdf | Download (370kB)
Available under University of Tasmania Standard License.
ABT-874, a fully human mAb that blocks the binding of IL-12 and IL-23 to their shared IL-12 receptor beta1, is currently being developed by Abbott Laboratories for the potential treatment of Crohn's disease and psoriasis. The compound is currently in phase III clinical trials for psoriasis and phase II trials for Crohn's disease. ABT-87 was previously being developed for the potential treatment of multiple sclerosis; however, by May 2007, development for this indication was discontinued.
|Journal or Publication Title:||Current Opinion in Investigational Drugs|
|Page Range:||pp. 515-522|
|Date Deposited:||11 Jun 2008 03:56|
|Last Modified:||18 Nov 2014 03:41|
|Item Statistics:||View statistics for this item|
Actions (login required)
|Item Control Page|